American Association for Cancer Research
10780432ccr180330-sup-196208_3_supp_4867170_pb952x.pptx (120.75 kB)

Supplementary Table S1 -S5 from Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients

Download (120.75 kB)
posted on 2023-03-31, 21:41 authored by Masato Kobayashi, Jin-Sung Chung, Muhammad Beg, Yull Arriaga, Udit Verma, Kevin Courtney, John Mansour, Barbara Haley, Saad Khan, Yutaka Horiuchi, Vijay Ramani, David Harker, Purva Gopal, Farshid Araghizadeh, Ponciano D. Cruz, Kiyoshi Ariizumi

Supplementary Table S1. Summary of MDSC analysis of metastatic cancer patents. aAll cancer patients are diagnosed as stage III or IV. Supplementary Table S2. Correlation of variables and expansion of DC-HIL+ MDSCs among colorectal cancer patients. Supplementary Table S3. % DC-HIL+ MDSC/PBMC in subgroups with vs. without radiotherapy. Supplementary Table S4. Reversing effects of anti-DC-HIL vs. anti-PDL1 mAb on MDSC suppressor function between two different treatments. Supplementary Table S5. DC-HIL and PDL1 expression in colorectal cancer tissues.


National Cancer Institute

Cancer Prevention Research Institute of Texas



Blocking the function of myeloid-derived suppressor cells (MDSC) is an attractive approach for cancer immunotherapy. Having shown DC-HIL/GPNMB to be the T-cell-inhibitory receptor mediating the suppressor function of MDSCs, we evaluated the potential of anti-DC-HIL mAb as an MDSC-targeting cancer treatment. Patients with metastatic cancer (n = 198) were analyzed by flow cytometry for DC-HIL or PDL1 expression on blood CD14+HLA-DRno/lo MDSCs. Their suppressor function was assessed by in vitro coculture with autologous T cells, and the ability of anti-DC-HIL or anti-PDL1 mAb to reverse such function was determined. Tumor expression of these receptors was examined histologically, and the antitumor activity of the mAb was evaluated by attenuated growth of colon cancers in mice. Patients with metastatic cancer had high blood levels of DC-HIL+ MDSCs compared with healthy controls. Anti-DC-HIL mAb reversed the in vitro function in ∼80% of cancer patients tested, particularly for colon cancer. Despite very low expression on blood MDSCs, anti-PDL1 mAb was as effective as anti-DC-HIL mAb in reversing MDSC function, a paradoxical phenomenon we found to be due to upregulated expression of PDL1 by T-cell-derived IFNγ in cocultures. DC-HIL is not expressed by colorectal cancer cells but by CD14+ cells infiltrating the tumor. Finally, anti-DC-HIL mAb attenuated growth of preestablished colon tumors by reducing MDSCs and increasing IFNγ-secreting T cells in the tumor microenvironment, with similar outcomes to anti-PDL1 mAb. Blocking DC-HIL function is a potentially useful treatment for at least colorectal cancer with high blood levels of DC-HIL+ MDSCs.See related commentary by Colombo, p. 453

Usage metrics

    Clinical Cancer Research



    Ref. manager